


PC19103B
Information Disclosure Statement For Appln. No. To be assigned
Div. of 10,460,010

Certificate of Mailing (37 C.F.R. §1.10):
I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail EL 969716585 US in an envelope
addressed to Mail Stop: Patent Applications,
Commissioner for Patents, PO Box 1450, Alexandria,
VA 22313-1450, on this 9th day of March 2004.

s/ 
Julie Agozino

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
COLLINS, ET AL

Group Art Unit: 1625

Serial No.: To be assigned
(DIV of 10/450,010)

Examiner: Charanjit Aulakh

Confirmation No.: TBA

Filed: Concurrently herewith

For: BENZOFUSED HETEROARYL AMIDE
DERIVATIVES OF THIENOPYRIDINES
USEFUL AS THERAPEUTIC AGENTS,
PHARMACEUTICAL COMPOSITIONS
INCLUDING THE SAME, AND METHODS
FOR THEIR USE

Mail Stop: Patent Applications
Honorable Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. § 1.97(b) or 1.97(c)

37 CFR § 1.97(b)

- ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

37 CFR § 1.97(c)

- ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of (1) a

that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the fee as set forth in § 1.17(p) to Deposit Account Number 500329.

- ☐ Applicant requests that the Examiner consider the following copending applications:


| Application Serial No. | Filing Date |
|------------------------|-------------|
| | |
| | |
| | |

- ☐ Copies of these copending applications are enclosed.
- ☒ Applicant hereby requests consideration of the Information Disclosure Statement, USPTO form 1449, submitted herewith. Copies of the cited references, except as noted below, are enclosed.
- ☒ This application is a continuation, divisional or continuation-in-part of Serial No. 10/460,010. Copies of the cited references, if not enclosed, are available in the file of the parent application or parents thereof.
- ☒ This application was filed after June 30, 2003, or entered U.S. national stage under 35 U.S.C. § 371, after June 30, 2003. Copies of U.S. Patents and U.S. Patent Application Publications are not enclosed. (1276 OG 55).
- ☐ Applicant hereby requests consideration of the enclosed International Search Report, which was received in a related international patent application.

The Commissioner is hereby authorized to charge any fee deficiency, including any fee required under 37 C.F.R. § 1.17(p), or credit any overpayment, to Deposit Account Number 500329. A duplicate copy of this form is enclosed.

Respectfully submitted,

Date: March 9, 2004



Stephen D. Prodruk
Attorney For Applicant
Registration No. 43,020

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 622-3087
Fax: (858) 678-8233

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|------------------------|
| Application Number | to be assigned |
| Filing Date | March 9, 2004 |
| First Named Inventor | Michael Collins et al. |
| Art Unit | 1625 |
| Examiner Name | Charanjit Aulakh |
| Attorney Docket Number | PC19103B |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | Cite No. ¹ | DOCUMENT NUMBER | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|---------------------|--------------------------|-------------------------------|--------------------------------|--|--|
| | | Number-Kind Code ² | | | |
| | A | 5,587,458 | 12-24-1996 | C. Richter King et al. | |
| | B | 5,747,498 | 05-05-1998 | Rodney Caughren Schnur | |
| | C | 5,792,783 | 08-11-1998 | Peng Cho Tang et al. | |
| | D | 5,834,504 | 11-10-1998 | Peng Cho Tang et al. | |
| | E | 5,861,510 | 01-19-1999 | Anthony Piscopio et al. | |
| | F | 5,863,949 | 01-26-1999 | Ralph P. Robinson et al. | |
| | G | 5,877,305 | 03-02-1999 | James S. Huston et al. | |
| | H | 5,883,113 | 03-16-1999 | Peng Cho Tang et al. | |
| | I | 5,886,020 | 03-23-1999 | Peng Cho Tang et al. | |
| | J | 6,071,935 | 06-06-2000 | Joseph P. Lyssikatos | |
| | K | 6,502,129 | 12-31-2002 | Daniel B. Stewart et al. | |
| | L | 6,492,383 | 12-2002 | Munchhof et al. | |
| | M | 6,225,318 | 05-01-2001 | | |
| | N | 6,492,383 | 12-10-202 | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|---------------------|--------------------------|--|-----------------------------------|--|---|----------------|
| | | Country Code ³ Number ⁴ Kind Code ⁵ (if known) | | | | |
| | AL | WO 90/05719 | 05-31-1990 | British Bio-Technology Limited | | |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901-04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|------------------------|
| Application Number | to be assigned |
| Filing Date | March 9, 2004 |
| First Named Inventor | Michael Collins et al. |
| Art Unit | 1625 |
| Examiner Name | Charanjit Aulakh |
| Attorney Docket Number | PC19103B |

| | | | | | |
|----|-------------|------------|------------------------------|--|--|
| AM | EP-0606,046 | 12-21-1993 | Novartis AG | | |
| AN | WO 95/19970 | 07-27-1995 | Warner-Lambert Company | | |
| AO | WO 95/21613 | 08-17-1995 | Sugen, Inc. & Yssum | | |
| AP | WO 95/23141 | 08-31-1995 | Pfizer Inc. | | |
| AQ | WO 96/14843 | 05-23-1996 | Cor Therapeutics, Inc. | | |
| AR | WO 96/27583 | 09-12-1996 | Pfizer Inc. | | |
| AS | WO 96/30347 | 10-03-1996 | Pfizer Inc. | | |
| AT | WO 96/33172 | 10-24-1996 | Pfizer Inc. | | |
| AU | WO 96/40142 | 12-19-1996 | Pfizer Inc. | | |
| AV | WO 97/13771 | 04-17-1997 | Glaxo Group Limited | | |
| AW | WO 97/13760 | 04-17-1997 | Glaxo Group Limited | | |
| AX | WO 97/22596 | 06-26-1997 | Zeneca Limited | | |
| AY | WO 97/32856 | 09-12-1997 | Zeneca Limited | | |
| AZ | WO 97/34876 | 09-25-1997 | Zeneca Limited | | |
| BA | WO 97/49688 | 12-31-1997 | Pfizer, Inc. | | |
| BB | WO 98/01113 | 01-15-1998 | Seiken Chemical Co., LTD. | | |
| BC | WO 98/02434 | 01-22-1998 | Glaxo Group Limited | | |
| BD | WO98/02438 | 01-22-1998 | Glaxo Group Limited | | |
| BE | WO 98/02437 | 01-22-1998 | Glaxo Group Limited | | |
| BF | WO 98/03516 | 01-29-1998 | Pfizer Inc. | | |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901-04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|------------------------|
| Application Number | to be assigned |
| Filing Date | March 9, 2004 |
| First Named Inventor | Michael Collins et al. |
| Art Unit | 1625 |
| Examiner Name | Charanjit Aulakh |
| Attorney Docket Number | PC19103B |

| | | | | | | |
|--|----|-------------|------------|------------------------------|--|--|
| | BG | WO 98/07697 | 02-26-1998 | Pfizer Inc. | | |
| | BH | WO 98/14451 | 04-09-1998 | Novartis AG | | |
| | BI | WO 98/23613 | 06-04-1998 | Pfizer Inc. | | |
| | BJ | WO 98/30566 | 07-16-1998 | Pfizer Inc. | | |
| | BK | WO 98/33768 | 08-06-1998 | Pfizer Products Inc. | | |
| | BL | WO 98/34918 | 08-13-1998 | Pfizer Inc. | | |
| | BM | WO 98/34915 | 08-13-1998 | Pfizer Inc. | | |
| | BN | WO 98/50356 | 11-12-1998 | Sugen, Inc. | | |
| | BO | WO 98/54093 | 12-03-1998 | Merck & Co., Inc. | | |
| | BP | WO 99/00797 | 01-07-1999 | Aplus Flash Technology, Inc. | | |
| | BQ | WO 99/10349 | 03-04-1999 | Zeneca Limited | | |
| | BR | WO 99/16755 | 04-08-1999 | Merck & Co., Inc. | | |
| | BS | WO 99/21845 | 05-06-1999 | Agouron Pharmaceuticals Inc. | | |
| | BT | WO 99/24440 | 05-20-1999 | Pfizer Products Inc. | | |
| | BU | WO 99/29667 | 06-17-1999 | Pfizer Limited | | |
| | BV | WO 99/35146 | 07-15-1999 | Glaxo Group Limited | | |
| | BW | WO 99/35132 | 07-15-1999 | Glaxo Group Limited | | |
| | BX | WO 99/52910 | 10-21-1999 | Pfizer Products Inc. | | |
| | BY | WO 99/52889 | 10-21-1999 | Pfizer Products Inc. | | |
| | BZ | WO 99/61422 | 12-02-1999 | Sugen, Inc. | | |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901-04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|------------------------|
| Application Number | to be assigned |
| Filing Date | March 9, 2004 |
| First Named Inventor | Michael Collins et al. |
| Art Unit | 1625 |
| Examiner Name | Charanjit Aulakh |
| Attorney Docket Number | PC19103B |

| | | | | | |
|---------|---------------|------------|----------------------|--|--|
| CA | WO 00/38665 | 07-06-2000 | G. D. Searle & Co. | | |
| CB | EP- 0 780 386 | 10-02-2002 | Hoffmann-La Roche AG | | |
| CC | EP- 0 931 788 | 11-16-2002 | Pfizer Inc. | | |
| CC 2 | WO 03/000,194 | 01-03-2003 | Pfizer, Inc. | | |
| CC 3 | WO 03/074,529 | 09-12-2003 | Pfizer, Inc. | | |
| CC 4 | WO 01/94353 | 12-13-2001 | Pfizer Products Inc. | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|----------------------|--------------------------|---|----------------|
| | CD | BAGSHAW, et. al., "Antibody-Directed Enzyme Therapy: A Review," <i>Drug Development and Research</i> , 1995, 220-230, 34. | |
| | CE | BERTOLINI, et. al., "A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immunosuppressive Drug," <i>Journal of Medicinal Chemistry</i> , 1997, 2011-2016, 40. | |
| | CF | BODOR, et. al., "Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems," <i>Advances in Drug Res.</i> , 1984, 224-331, 13. | |
| | CG | BUNDGAARD, et. al., <i>Design and Application of Prodrugs, Drug Design and Development</i> , Harwood Academic Press, 1991. | |
| | CH | BUNDGAARD, et. al., <i>Design of Prodrugs</i> , Elsevier Press, 1985, New York. | |
| | CI | BUTTERY, et. al., "Preparation of 2,3-Disubstituted Indoles from Indole-3-carboxylic Acids and Amides by Deprotonation," <i>Journal of Chem. Soc. Perkin Trans</i> , 1993, 1425-1431. | |
| | CJ | PAGANO, Michele ed., <i>Cell Cycle: Materials and Methods</i> , 1995, Berlin, Germany. | |
| | CK | FLEISHER, et. al., "Improved Oral Drug Delivery: Solubility Limitations Overcome by the Use of Prodrugs," <i>Advanced Drug Delivery Reviews</i> 1996, 115-130, Vol. 19. | |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901-04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|------------------------|
| Application Number | to be assigned |
| Filing Date | March 9, 2004 |
| First Named Inventor | Michael Collins et al. |
| Art Unit | 1625 |
| Examiner Name | Charanjit Aulakh |
| Attorney Docket Number | PC19103B |

| | | |
|----|--|--|
| CL | GREEN, T., et. al., <u>Protecting Groups in Chemical Synthesis (3rd Edition)</u> , 1999, John Wiley & Sons, New York. | |
| CM | MOHAMMADI., et. al., "Identification of Six Novel Autophosphorylation Sites on Fibroblast Growth Factor Receptor 1 and Elucidation of Their Importance in Receptor Activation and Signal Transduction," <i>Molecular Cell and Biology</i> , 1996, 977-989, Vol. 16, No. 3. | |
| CN | PARAST, et. al., "Characterization and Kinetic Mechanism of Catalytic Domain of Human Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase (VEGFR 2 TK), a Key Enzyme in Angiogenesis," <i>Biochemistry</i> , 1998, 16788-16801, 37. | |
| CO | ROBINSON, et. al., "Discovery of the Hemifumarate and (a-L-Alanylogy) methyl Ether as Prodrugs of an Antirheumatic Oxiindole: Prodrugs for the Enolic OH Group," <i>Journal of Medicinal Chemistry</i> , 1996, 39, 1, 10-18. | |
| CP | SHAN, et. al., , "Prodrug Strategies Based on Intramolecular Cyclization Reactions," <i>Journal of Pharmaceutical Science</i> , 1997, 765-767, Vol. 86, No. 7. | |
| CQ | STILL, et. al., "Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution," <i>Journal of Organic Chemistry</i> , 1978, 2923-2925, Vol 43, No. 14. | |
| CR | SWAIN, et. al., "Novel 5-HT ₃ Antagonists: Indol-3-ylspiro(azabicycloalkane-3,5' (4'H)-oxazoles)," <i>Journal of Med. Chemistry</i> , 1992, 1019-1031, 35. | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901-04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.